NEW YORK (GenomeWeb News) – Alameda, Calif.-based Singulex announced yesterday that it is collaborating with the Swiss pharmaceutical company Novartis and that it has opened a new facility in Paris to serve European collaborators.
Under the agreement, a Novartis facility in Basel, Switzerland, has acquired Singulex’s Erenna system, which is used for detecting changes in protein biomarkers in samples from several species. In addition, Singulex plans to help Novartis create biomarker assays related to the pharmaceutical company’s drug development programs.
Terms of the collaboration were not disclosed.
Meanwhile, the Singulex center in France is intended to bring Singulex’s biomarker diagnostic systems and immunoassay technology, including Erenna, closer to its European partners.